ALK | Allergy solutions for life
ALK

Celebrating the past and future of allergy solutions for life

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy
<p><iframe height="315" src="https://player.skyfish.com/?v=https://video.skyfish.com/943a10db-106f-4de5-882b-15e46428e763/AppleHLS1/stream-315260-58265547.m3u8&media=58265547" style="border: 0" title="Skyfish video" width="560"></iframe></p>

News

  • Post date
    02/03/2023
    Regulatory filing for house dust mite allergy tablet accepted for review in China
  • Post date
    02/03/2023
    Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
  • Post date
    01/27/2023
    Release date of annual report 2022 for ALK and audio cast
  • Post date
    12/21/2022
    Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK
  • Post date
    12/19/2022
    ALK – Financial calendar for the 2023 financial year
  • Post date
    11/30/2022
    Management change at ALK
  • Post date
    11/10/2022
    Nine-month interim report (Q3) 2022
  • Post date
    11/03/2022
    Release date of nine-month interim report (Q3) 2022 for ALK and audio cast
  • Post date
    08/25/2022
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.